Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Published Online: 2017-01-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Alessandro Granito•Ann-Lii Cheng•Annette Baumhauer•Gerold Meinhardt•Gianluca Masi•Guohong Han•György Bodoky•Isabelle Ollivier-Hourmand•Jean-Pierre Bronowicki•Jordi Bruix•Josep M Llovet•Marc Pracht•Marie-Aude LeBerre•Masatoshi Kudo•Olivier Rosmorduc•Osamu Yokosuka•Paul J Ross•Philippe Merle•René Gerolami•Richard S Finn•Shukui Qin•Tianqiang Song•Valeriy Breder•Yi-Hsiang Huang
